Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
JNJ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$140.68 - $169.99
Previous CloseN/A
Volume3.80M
Average Volume (3M)9.21M
Market Cap
$394.32B
Enterprise Value$365.36B
Total Cash (Recent Filing)$24.11B
Total Debt (Recent Filing)$36.63B
Price to Earnings (P/E)28.3
Beta0.23
Next Earnings
Apr 15, 2025EPS Estimate
2.65Last Dividend Ex-Date
Feb 18, 2025Dividend Yield3.03%
Share Statistics
EPS (TTM)5.80
Shares Outstanding2,409,847,700
10 Day Avg. Volume9,133,016
30 Day Avg. Volume9,207,390
Financial Highlights & Ratios
PEG Ratio7.65
Price to Book (P/B)N/A
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)14.10
P/FCF Ratio14.10
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.78
Enterprise Value/Ebitda12.81
Forecast
1Y Price Target
$168.27Price Target Upside3.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Pharmaceutical DevelopmentIcotrokinra achieved clinical remission rates up to 30.2% at week 12 and met the primary endpoint of clinical response at all icotrokinra doses evaluated.
Product InnovationA key growth driver is expanding robotics and AI in knees, hips, and trauma, enhancing surgical precision and efficiency.
Revenue GrowthJNJ Ortho aims to accelerate organic revenue growth to the top end of the 3%-5% WAMGR by simplifying operations, expanding robotics & AI-powered digital solutions, and driving ASC growth.
Bears Say
Clinical TrialsJNJ announced that the company discontinued aticaprant’s Phase 3 VENTURA trials in adjunctive major depressive disorder.
Product DevelopmentIt is still somewhat unclear to what degree patients will prefer a once-daily oral pill with food restrictions relative to quarterly Skyrizi maintenance dosing.
---
Ownership Overview
0.04% Insiders
18.79% Mutual Funds
14.38% Other Institutional Investors
45.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $140.68 and its highest was $169.99 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $394.32B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Apr 15, 2025 which is in 21 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jan 22, 2025. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.992 by $0.048.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 3.03%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.65.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,847,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.04 in its last earnings report, beating expectations of $1.992. Following the earnings report the stock price went down -1.939%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
---
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$168.27 (3.05% Upside)
$168.27 (3.05% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 92%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 603.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.43%
12-Months-Change
Fundamentals
Return on Equity
20.06%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
---
JNJ Company Deck
---
JNJ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Johnson & Johnson showed robust growth in sales and innovation in 2024, particularly in the Innovative Medicine and MedTech sectors. However, earnings were negatively impacted by STELARA biosimilars and recent acquisitions, while challenges in China and decreased margins were noted.Read More>---
JNJ Sales Breakdown
64.13% Innovative Medicine
35.87% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$168.27
▲(3.05% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
23/23 ratings generated profit
1 Year Average Return
+9.75%
reiterated a buy rating 10 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.75% per trade.
---